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Currently, the majority of cancer treatments rely on a coordinated
multi-faceted approach, utilising evidence gathered from large-scale
animal studies and human clinical trials, in order to determine an
optimal treatment regimen. Unfortunately, the efficacy of many
therapies is relatively poor with some causing severe side effects and
many tumours having five year survival rates not exceeding 50%1-2. It is
becoming increasingly clear that the variability in disease patterns and
cancer response is due to the unique genetic background and immune
response of each patient3-5. Hence the best way to deal with individual
tumours is to optimise the treatment on a person-by-person basis; this
is not easily done with current methodologies6-7. 
Traditionally, development of treatments for diseases such 
as cancer use simple in vitro cell culture models and/or animal models
to understand the complex patho-physiology of the disease6. 
Microfluidic technology has great potential for complementing and, in some instances, replacing the use of animal
models in the testing of medicines and in developing personalised treatments for cancer patients. The maintenance
of tissue in an in vivo-like state provides a platform upon which normal and diseased tissue biology can be
investigated in a novel way. This review describes the use of microfluidic technology for the maintenance of tissue
samples ex vivo and the current state of play for the use of this technology in the replacement of animal models,
with a focus on cancer.
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Cell culture models typically use a single cell type grown in a 
monolayer, whereas the majority of cells in vivo grow in three
dimensional (3D) structures consisting of many different cell types in a
unique spatial arrangement, interweaved with
extracellular matrix (ECM)8-10. It is the sum of all
these interactions between neigh bouring cells
and the ECM that guides developmental
processes central for function. Although the
fabrication of 3D spheroids constructed from different cell types is
designed to try and mimic these interactions, the complex in vivo
nature is still not matched11. 
Approaches using xenograft models by Stebbing et al.12 have shown
promising data towards personalised cancer treatment: resected
tumour is divided, grafted subcutaneously into immunocompromised
mice, propagated and passaged into further generations to provide
multiple animals carrying the same tumour. These can then be tested
with a variety of drugs alone or in combination to establish which works
most effectively. However, the procedures are lengthy with the growing
process taking up to six months, potentially leading to a delay in
patients recieving the best treatment, and the mouse avatars cost tens
of thousands of dollars to generate and maintain with graft success
rates of less than 100%12-13. Furthermore, the approach uses a relatively
large number of animals which comes at a time when society is keen to
reduce the numbers of animals used in research. Finally, there is the
obvious limitation in that substantial differences do exist in the systems
and mechanisms between humans and mice.
Microfluidics is a technology which began to emerge in the 1950s
with the idea of manipulating small volumes of
fluids to allow controlled mixing and reaction,
and has rapidly evolved into devices which
miniaturise laboratory techniques with high
sensitivity and specificity. Two main categories
of device are available for the maintenance of cells and tissue, including
droplet-based and continuous-flow, with and without the integration of
analytical modules such as polymerase chain reaction and flow
cytometry (see Tanweer et al.14 for a review of microfluidic devices in
head and neck cancer). The current review focusses on continuous flow
devices for the maintenance and interrogation of human tissue ex vivo,
with the aim of preserving tissue in its 3D in vivo-like structure, retaining
complex cell-to-cell and cell-to-matrix interactions.
Tissue-based microfluidics
Microfluidic tissue culture mimics the systems and pressures of the
human body with continuous perfusion, allowing delivery of nutrients
to multiple pieces of the same tissue in parallel, with the simul-
taneous removal of waste (Figure 1)15-16. The use of microfluidics to study
human tissue offers an innovative method for studying the in vivo
environment compared with cell lines – which are artificially
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Figure 1: (a) Photograph of parallel devices. (b) Schematic of the microfluidic design and setup maintained at 37°C with constant media influx and simultaneous removal 
of waste products
Approaches using xenograft models
have shown promising data towards
personalised cancer treatment 
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immortalised for long-term culture and lack
the cellular interactions – and animal
models, which may not physiologically 
or genetically represent true tumour or
human physiology. 
The culture of human tissue in a chip
and, more importantly, human tumour tissue
in a chip allows for the correct micro-
environment to be maintained ex vivo and
for stromal-epithelial interactions to be
studied14. The maintenance of tissue in this
manner allows the effect of various drug
combinations, irradiation, and chemical
reactions to be monitored and assessed with
the potential of identifying optimal treat -
ment strategies for the individual in a timely
manner prior to first administration to the
patient. For example van Midwoud et al.17
described how microfluidics was used in
combination with precision-cut liver slices as
an improved biomimetic system,17 incorpor -
ating a micro-chamber for slice “perfusion”
under continuous flow to perform drug metabolism studies.
Alternatively, Sylvester et al.16 monitored the ability of chemo -
therapeutic drug combinations to kill head and neck tumour tissue
(HNSCC) biopsies. 
Since the first evidence of microfluidic culture of rat brain tissue
slices in 200318, various devices have been designed and utilised for the
culture of both animal and human tissue under
ex vivo conditions, the most recent of which
(since 2013) are summarised in Table 1 (page 15).
These studies show the diverse range of uses
that microfluidic tissue culture can be applied
to, from the analysis of cell migration in the retina19 through to the
commercialisation of the artery-on-a-chip model, to assess calcium
dynamics and vascular tone20-21. Studies such as that by Chang et al.22
demonstrate the intricate delivery of parallel drugs simultaneously or
sequentially to the same piece of mouse brain tissue and are able to
overcome the problems of tumour heterogeneity between patients and
between tumours of different origin; a further benefit is the ability to
establish multiple biopsies to assess tumour heterogeneity. Research at
the University of Hull has focussed on the use of a simple, continuous
flow, glass chip design (Figure 2; page 15) for the maintenance and
interrogation of a selection of human tissues, described below. 
Head and neck cancer on a chip
Extensive work has been carried out using HNSCC maintained in
microfluidic devices in which the effects of chemotherapeutic drugs,
alone and in combination, and external beam radiation have been
investigated in terms of cell death and proliferation16,25,28. Using the glass
microfluidic device (Figure 2; page 15), head and neck tumour tissue
weighing approximately 10mg with a volume of 8mm3 was maintained
for nine days to demonstrate the synergistic cytotoxic effects of
chemotherapeutic drug combinations28. Further experiments extended
the tissue incubation period out to 15 days allowing the assessment of
tissue response to irradiation. It was demonstrated that apoptotic
response to irradiation could be detected in the tissue following as little
as 2Gy, that the effect was dose dependant and that a fractionated
course of 5 x 2Gy, similar to that received by patients, demonstrated a
significantly greater apoptotic response compared with the single 
2Gy dose25. The combination of these studies with on-chip analyses,
such as those developed by Woods et al.29 and
others30-31, not only provides a unique platform
for the development of assays to predict
response of any solid tumour to various
treatments prior to commencing treatment,
but also allows the investigation of tumour biology in a pseudo in vivo
environment without the need for animal experimentation.
Cardiac tissue on a chip
A similar device was developed to maintain heart tissue samples 
(Figure 2; page 15) taken from either a human or rat with the addition of
electrical stimulation to emulate the beating of heart tissue in vivo. 
The viability of the cardiac tissue was determined by biochemical
measurement of the release of lactate dehyrogenase (LDH) and
hydrogen peroxide as markers of tissue damage. This device also
allowed primary investigations into electrochemical monitoring of
reactive oxygen species and lactate during perfusion of the tissue to
address clinically relevant issues such as ischemia reperfusion32.
Liver tissue on a chip
Work by Hattersley et al.33 repeatedly demonstrated the ability of the
Hull microfluidic device to maintain viable, functional liver tissue for up
to 72 hours, measured using LDH and water soluble tetrazolium-1
release, histology, as well as albumin and urea production. This work
provided a platform to study toxicity whilst the liver was perfused with
ethanol33. The ability to measure changes in production of a normal
tissue product in the effluent over time, with varying concentrations of
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ethanol assault, show the power of the
approach for real-time monitoring. 
Pitfalls and limitations of
microfluidic culture 
Microfluidics has yet to make the impact on
science it deserves, as the technology
requires a range of subsystems and com -
ponents with the integration of complete
systems. As G.M Whitesides, a founding
father of this technology stated, “the field of
microfluidics is in early adolescence, and still
lacks both these essential requirements, in
addition to the integration of components
into systems that can be used by non-
experts. As a field, it is a combination of
unlimited promise, pimples and incomplete
commitment. This is a very exciting time for the field, but we still do not
know exactly what it will be when it grows up”34. This comment was
made in 2006 but remains true for clinical use in 2016 as the combina -
tion of scientific disciplines has not yet truly worked together to fulfil
the technology’s potential.
To date, much of the tissue-on-chip research has focussed on
MICROFLUIDICS
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Figure 2: Continuous flow microfluidic devices used in Hull for the culture of (a) HNSCC and liver tissue with (b)
subsequent LINAC irradiation and (c) heart tissue with electrical stimulation
Table 1: Published literature on the use of microfluidics for whole tissue culture from January 2013-December 2015
Title Tissue Summary
Micro-dissected tumour tissues on Prostate and ovarian cancer xenograft ‘Spheroid sized’ micro-dissected tissues (MDTs; 380µM diameter and 300µM height) 
chip: an ex vivo method for drug and primary serous ovarian cancer maintained in an MF device with periodic replacement of perfusion media for up to
testing and personalised therapy23 eight days. Viability was determined on-chip by confocal microscopy and off-chip by flow
cytometry on dissociated cells (annexin V and 7AAD). Carboplatin chemosensitivity testing 
on primary ovarian cancer tissue was shown as proof of concept. 
Retina-on-a-chip: an MF C57BL/6 and CX3CR1-GFP Culture of whole retina for up to four days enabled tissue maintenance and localised reagent
platform for point access mouse retina delivery to stimulate cell migration; an inflammatory response was induced by LPS.
signalling studies19 Viability was shown by active uptake of neural tracer, cholera toxin beta, which is specific to
retinal ganglion cells. Migration analysis was conducted on chip by live retina imaging using
laser scanning confocal microscopy for GFP+microglia. 
High temporal resolution Human adipose tissue (hAT) hAT biopsies of 3mm diameter maintained for up to seven days were used to study insulin
detection of patient-specific resistance in healthy vs. type 2 diabetes mellitus patients. Viability was evaluated by
glucose uptake from human MTT assay and morphology by off-chip H&E staining. Insulin resistance was measured
ex vivo adipose tissue on-chip24 by glucose uptake. 
Artery-on-a-chip platform for Olfactory artery segments An MF platform for automated assessment of small blood vessels under close-to in vivo
automated, multimodal assessment C57BL/6 mice conditions. Previous work developed the first artery-on-a-chip platform for culture of artery
of cerebral blood vessel structure segments for 24h which was commercialised in 2013 by Quorum Technologies21.
and function20 This extended work demonstrates assessment of calcium dynamics and vascular tone in
parallel. Fixation and staining of the pressurised segment on chip are also shown. 
Parallel microfluidic E18-P7 embryonic or neonatal mice An MF device incubates a brain slice (300µM) for up to seven days. Selective chemical 
chemosensitivity testing on brains and GBM xenografts delivery along micro channels was shown using fluorescein. Model cytotoxic agents of 
individual slice cultures22 concentration were applied to the same tissue slice and response monitored by imaging of
increasing markers for apoptosis and cell death. GFP-labelled human xenograft slices (400µM)
were treated with temozolomide, response measured by reduction in GFP-labelled glioma cells.
Analysis of radiation-induced Head and neck squamous Culture of HNSCC biopsies (5-10mg) for four days to analyse response of tissue to 
cell death in head and neck cell carcinoma radiation therapy (2-40Gy). LDH measurable in the effluent showed cell death, and
squamous cell carcinoma and immunohistochemistry for cleaved cytokeratin-18 was used to calculate apoptotic index.
rat liver maintained in 
microfluidic devices25
An MF device designed Mouse pancreatic islets MF device designed to study endocrine cells and ultimately to facilitate islet priming prior to
to induce media flow throughout transplantation. Device designed to reduce shear stress on islets seen in previous devices.
pancreatic islets while limiting Analysis performed by confocal microscopy off-chip with endothelial cell marker
shear induced damage26 immunofluorescence, shear stress monitored by glucose-stimulated Ca2+ response. 
Skin and hair on-a-chip: in vitro Prepuce and occipital & temporal Device developed to prolong culture period of skin biopsies and skin equivalents.
skin models versus ex vivo scalp skin follicular unit 5mm punched biopsies of prepuce and ex vivo FUEs were cultured separately in the device
tissue maintenance with extracts (FUEs) for 14 days. Samples were removed, snap frozen and cryosectioned for subsequent analysis
dynamic perfusion27 of morphology by H&E staining and immunofluorescence for proliferation (Ki67) and
apoptosis (TUNEL).
Development of microfluidic- Head and neck squamous HNSCC biopsy tissue (5-10mg) maintained for up to nine days was used to allow testing of
based analytical methodology cell carcinoma multiple chemotherapy agents (cisplatin, fluorouracil and docetaxel) alone and in
for studying the effects of combination. Cell death was analysed by LDH in the effluent and viability was measured
chemotherapy agents on by WST-1 proliferation assay.
cancer tissue16
7AAD, 7-Aminoactinomycin D; GFP, green fluorescent protein; LPS, lipopolysaccaride; H&E, haematoxylin and eosin; MF, microfluidic; GMB, glioblastoma; HNSCC, head and neck squamous cell carcinoma; 
Gy, gray; LDH, lactate dehydrogenase; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling; WT, wild type. Studies on human tissue samples are highlighted in green.
dtr116 Greenman_Layout 1  08/03/2016  09:39  Page 4
demonstrating the ability of a microfluidic
device to measure a particular analyte in the
effluent or tissue, following some form of
treatment. These studies tend to be led by
either biology or chemistry researchers
approaching a question from their discipline and many of these studies
have shown it is possible to study individual parameters. The ability of
these parameters to become integrated in a way to address a bigger
question such as delivering personalised medicine, or offering a robust
methodology for screening off-target organ
drug effects, has not yet been demonstrated.
One of the reasons for this is the need for long-
term investment and the input of multiple
scientific disciplines, for example, clinicians,
engineers and modellers in addition to chemists and biologists as the
coupling of tissue to ‘downstream’ analysis modules requires
compromises in microfluidic chip design, tissue maintenance 
and analyte detection. However, the goals of improved treatment at
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reduced cost whilst using fewer animals provides a strong impetus for
the technology to deliver.
Impact towards reducing animal models
The majority of current clinical research methodology uses animal
models that are induced into the diseased state and treated with test
substances at some time in their lives. Despite many known limitations,
these animal models are commonly used, and for drug testing are often
explicitly required. An aim of tissue-on-a-chip research is to reduce the
number of animals used for the study of cancer and its treatment,
firstly because increasingly data suggest the animal models do not
adequately represent the human disease but also because the morality
for the use of vast numbers of animals in research is continually being
questioned. According to UK Home Office statistics there has been an
increase year on year in the number of animals used for research since
1995, and in 2013 the number of animals used in cancer research was
500,769 (UK’s latest statistics of Scientific Procedures on Living Animals),
a 13% increase from the previous year35. The adoption of microfluidic
technology to maintain patient biopsies could offer a viable
replacement option for many animal models, being not only cost
effective but simple to mass produce and operate, allowing for better
science in the future, using human tissue to represent human disease. 
Conclusion
Microfluidic tissue culture is well on the way to becoming a reputable
substitute for animal models in the study of human disease, but
investment and wide-spread adoption are required to deliver the new
platforms and concomitant health benefits.
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